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T
he human body is composed of over 400 dis-
tinct cell types, each originating from a totipotent
zygote (Figure 1, panel a) (1). During fetal devel-
opment, cell differentiation arises through a succession
of speciﬁcation events, including the establishment of a
pluripotent inner cell mass, its conversion into three
multipotent germ layers (ectoderm, mesoderm, and
endoderm), and the creation of increasingly specialized
cells in a stepwise manner (Figure 1, panel b). These cell
fate choices must be coordinated in both space and
time to achieve a functional body plan, and many of the
molecular reactions and interactions that regulate cell
speciﬁcation and tissue patterning have now been iden-
tiﬁed through large-scale mutagenesis screens in model
organisms. In particular, a suite of intercellular signal-
ing mechanisms, commonly referred to as developmen-
tal pathways, are used iteratively and combinatorially
to coordinate cell fate and function during embryogen-
esis, as well as to control postnatal tissue homeostasis.
These developmental pathways include Hedgehog (Hh),
Wnt, transforming growth factor- (TGF), ﬁbroblast
growth factor (FGF), and Notch signaling, and the molec-
ular mechanisms and physiological roles of each signal-
ing process are largely conserved across the animal
kingdom (2–6). Cell fate choices actuated through these
pathways are inﬂuenced and reinforced by epigenetic
processes such as chromatin remodeling, thereby
achieving the stereotypic cellular diversity required for
organismal function amidst genomic uniformity.
Small molecules that can control cell fate have gar-
nered considerable interest in recent years, as the criti-
cal roles of stem cell self-renewal and differentiation in
human physiology have become better understood. A
number of these compounds target speciﬁc develop-
mental pathways, modulating the biogenesis and/or
secretion of the extracellular ligands that initiate each
pathway (e.g., the Hh, Wnt, TGF, and FGF families of se-
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ABSTRACT Controlling cell fate is essential for embryonic development, tissue
regeneration, and the prevention of human disease. With each cell in the human
body sharing a common genome, achieving the appropriate spectrum of stem cells
and their differentiated lineages requires the selective activation of developmen-
tal signaling pathways, the expression of speciﬁc target genes, and the mainte-
nance of these cellular states through epigenetic mechanisms. Small molecules
that target these regulatory processes are therefore valuable tools for probing and
manipulating the molecular mechanisms by which stem cells self-renew, differen-
tiate, and arise from somatic cell reprogramming. Pharmacological modulators of
cell fate could also help remediate human diseases caused by dysregulated cell
proliferation or differentiation, heralding a new era in molecular therapeutics.
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tors, or signaling events involving downstream effec-
tors and transcription factors. Other fate-modulating
chemicals target factors that dictate the responsive-
ness of cells to external cues, such as chromatin remod-
elling enzymes and cell cycle regulators. Using these
molecular probes, biologists have gained important in-
sights into the biochemical mechanisms that determine
cell fate choice, both in cell culture and in whole
organisms.
Small molecules that target developmental path-
ways and other cell speciﬁcation mechanisms also have
the potential to transform how we treat certain dis-
eases and disorders. Ontogeny and oncogenesis are
mechanistically linked, as inappropriate cell fate choice
can promote the onset and/or maintenance of several
tumors, perhaps by engendering stem cell-like cancer
cells (Figure 1, panel b) (2, 3, 5–7). Compounds that in-
hibit these processes could therefore be more efﬁca-
cious than conventional chemotherapies, which indis-
criminately target proliferating cells and commonly
produce severe side effects. There is even the exciting
prospect that pharmacological reagents might be able
to enhance or create de novo regenerative activities that
involve pluripotent or multipotent cells, thereby remedi-
ating traumatic injuries or degenerative diseases.
In this review we summarize recent progress toward
developing small-molecule regulators of cell fate
(Table 1). Compounds that modulate the Hh, Wnt, TGF,
FGF, or Notch pathways will ﬁrst be described, since
these intercellular signaling mechanisms are primary
mediators of tissue patterning and regeneration. We will
then survey how phenotype-based screens have been
used to identify other compounds that promote stem
cellself-renewal,thedifferentiationofspeciﬁccelltypes,
or the reprogramming of somatic cells into pluripotent
populations. The examples described herein are not in-
tended to be comprehensive, and readers are encour-
aged to examine previous reviews of fate-modulating
compounds (8, 9). Rather, these selected studies illus-
trate the biological concepts, experimental approaches,
and therapeutic possibilities that are associated with
the discovery of small-molecule regulators of cell fate.
We conclude our review with a discussion of the poten-
tial of this emerging ﬁeld, its current limitations, and fu-
ture challenges for the chemical biology community.
Hh Pathway Modulators. Hh signaling is perhaps the
developmental pathway that has been most extensively
Figure 1. Progenitor cell self-renewal and differentiation contribute to tissue patterning and tumorigenesis. a) Examples of special-
ized cell types associated with different human tissues and organs. b) Schematic representation of the self-renewal and differen-
tiation of progenitor cells, in both normal and oncogenic contexts. Depicted derivatives of the primary germ layers are illustrative
rather than inclusive.
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tion promotes the self-renewal of certain progenitor
populations such as hair follicle stem cells and
cerebellargranuleneuronprecursors(10,11).Hhsignal-
ing also regulates neural cell fate along the dorsal-
ventral axis of the developing spinal cord (12), anterior-
posterior digit identity (13), and retinal cell
diversiﬁcation in the nascent eye (14). In each of these
systems, palmitoyl- and cholesteryl-modiﬁed Hh ligands
(in mammals, Sonic (Shh), Indian (Ihh), and Desert
(Dhh) Hedgehog) are released in a spatially restricted
manner by Hh-producing cells, creating a gradient of Hh
protein (2). Hh biogenesis and secretion are speciﬁ-
cally regulated by the transmembrane proteins Hh acyl-
transferase (Hhat) and Dispatched (Disp), and respon-
sive cells then express speciﬁc target genes in a Hh
concentration-dependent manner, generating an orga-
nized array of discrete cell types (Figure 2, panel a).
Reception of the Hh signal involves several con-
served signaling proteins, including the twelve-pass
transmembrane receptor Patched1 (Ptch1), the G
protein-coupled receptor (GPCR)-like protein Smooth-
ened (Smo), the nucleocytoplasmic factor Suppressor
of Fused (Sufu), and the Gli family of transcription fac-
tors (Gli1, Gli2, and Gli3) (2). In the absence of Hh li-
gand, Ptch1 inhibits the activity of Smo, permitting the
sequential phosphorylation of Gli2 and Gli3 by protein
kinase A (PKA), glycogen synthase kinase-3 (GSK3), and
casein kinase 1 (CK1). These phosphorylation events
create docking sites for ubiquitination machinery, lead-
ing to proteolytic processing of the Gli proteins into
N-terminal transcriptional repressors or their complete
degradation. Hh ligands directly inhibit Ptch1 and there-
fore activate Smo, promoting the stabilization of full-
length Gli2 and Gli3 and their conversion into transcrip-
tional activators. Smo activation appears to also shield
the Gli proteins from the repressive effects of Sufu,
which binds to Gli factors and inhibits their activity
through multiple mechanisms. Hh target genes include
Ptch1 and Gli1, creating negative and positive feedback
loops, respectively.
Consistent with the multiple patterning roles of Hh
signaling, dysregulation of any of these events can
have severe physiological consequences. Loss-of-
function mutations in SHH, DHH, and GLI2 and putative
gain-of-function mutations in PTCH1 have been associ-
ated with birth defects such as holoprosencephaly and
gonadal dysgenesis (15–18), and genetic lesions at the
Figure 2. Hh and Wnt signaling pathways. Signaling proteins associated with Hh (a) and Wnt (b) pathway regulation
are shown. Components or processes that currently can be targeted by small molecules to achieve selective pathway
control are labeled with green (agonist) and red (antagonist) hexagons. Direct small moleculeprotein interactions
are depicted when known.
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rant activation of the Hh pathway is associated with
the onset and/or progression of several cancers such
as basal cell carcinoma (20), medulloblastoma (21, 22),
and pancreatic adenocarcinoma (23, 24). These onco-
genic events can result from inappropriate autocrine or
paracrine Hh signaling, as well as pathway-activating
mutations in PTCH1, SMO,o rSUFU.
In principle, small molecules could target any of
these signaling events, from Hh ligand biogenesis to Gli-
dependent transcription. In practice, however, nearly
all known small-molecule modulators of the Hh path-
way target Smo, perhaps reﬂecting the pharmacologi-
cal sensitivity of GPCR family members and related
proteins. The ﬁrst Hh pathway inhibitor to be discov-
ered was the steroid alkaloid cyclopamine, a plant-
derived teratogen associated with an outbreak of cyclo-
pic lambs in Idaho during the 1950s (25). Genetic and
biochemical analyses conducted nearly half a century
later established that cyclopamine directly inhibits Smo
(26), and subsequent high-throughput screens of syn-
thetic chemical libraries have identiﬁed numerous other
Smo inhibitors (27–30), as well as Smo agonists such
as SAG and purmorphamine (27, 31–33). Compounds
that target other Hh signaling proteins have been more
elusive. One notable exception is the 12-membered
macrocycle robotnikinin, which was discovered through
a small-molecule microarray screen for compounds
that can bind recombinant Shh (34). Robotnikinin inhib-
its Hh pathway activation induced by Shh ligand, but it
hasnoinhibitoryeffectontheHhtargetgeneexpression
in Ptch1/ ﬁbroblasts or cells activated with purmor-
phamine. These results indicate that robotnikinin may
prevent Shh from binding to Ptch1, although the molec-
ular details of this mechanism have not yet been
established.
Until recently, the standard method for blocking Hh
pathway activity downstream of Smo was to treat Hh-
responsive cells with forskolin, which activates adeny-
late cyclase, increases cAMP levels, and promotes the
inhibition of Gli function by PKA. The pleiotropic effects
of forskolin, however, have prompted a search for
mechanistically distinct Hh pathway inhibitors that act
downstream of Smo, and a few compounds that are epi-
static to endogenous or overexpressed Gli activators
have now been reported. For example, the synthetic
molecules GANT-58 and GANT-61 were identiﬁed in a
screen for compounds that can block Hh pathway activ-
ity induced by the overexpression of Gli1 in HEK-293T
cells, and natural product inhibitors of Gli-mediated
transcription were found in a similar Gli1 overexpres-
sionassay(35,36).FouradditionalGliantagonists(HPIs
1–4) were recently discovered in a cell-based screen
for SAG repressors (37). Although the precise mecha-
nisms of these Hh pathway inhibitors remain unknown,
itisunlikelythattheydirectlytargettheGlifamilyoftran-
scription factors. Rather, these compounds probably in-
teract with endogenous factors that control Gli function
and therefore could be valuable probes of these regula-
tory mechanisms.
Several of these Hh pathway modulators have been
applied toward the regulation of cell fate in vitro and
in vivo. The SAG class of Smo agonists has been used
to differentiate motor neurons from mouse embryonic
stem cells (ESCs) and to expand neuronal precursor
cells in animal models of spinal cord injury (38, 39).
SAG-related compounds have also successfully pro-
moted hair growth in mouse
skin (40), and purmorphamine
was originally found in a
screen for osteogenic com-
pounds (33). Smo antagonists
have been equally effective in
murine models of medullo-
blastoma (41), pancreatic ad-
enocarcinoma (23, 24, 42),
and other tumors, and several
pharmaceutical companies
are developing these com-
pounds as targeted chemo-
therapies. The Genentech/
Curis inhibitor, GDC-0449, has
demonstrated efﬁcacy against
metastatic basal cell carci-
noma in phase I clinical trials
(28), and lead compounds
from Inﬁnity Pharmaceuticals
and Bristol Meyers Squibb/Ex-
elixis are now in phase I trials
as well. It will be interesting to
determine whether down-
stream Hh pathway inhibitors
are comparably active against
murine tumor models, espe-
cially since Smo mutations
that convey GDC-0449 resis-
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Differentiation: The process by which
unspecialized cells acquire speciﬁc functions,
allowing the generation of complex tissues
and organs. Differentiation is frequently
controlled by cell signaling pathways and
maintained through epigenetic mechanisms.
Ectoderm: The outer germ layer that gives rise to
skin, the nervous system, and sensory
organs.
Endoderm: The inner germ layer that gives rise to
respiratory and digestive organs.
Embryonic stem cells: Pluripotent cells derived
from embryos that can be propagated in
culture.
Feeder cells: Cells co-cultured with pluripotent
cells to prevent their differentiation. Feeder
cells are typically mouse or human embryonic
ﬁbroblasts.
Induced pluripotent stem cells: Pluripotent cells
obtained through the reprogramming of
differentiated cells. Induced pluripotent stem
cells are functionally similar to embryonic
stem cells.
Mesoderm: The middle germ layer that gives rise
to muscle, bone, connective tissues, and
blood cells.
Multipotent cells: Cells that can give rise to more
than one cell type of the body.
Pluripotent cells: Cells that can give rise to all
differentiated cell types of the body but not
extraembryonic tissues.
Totipotent cells: Cells that give rise to all
differentiated cell types of the body and
extraembryonic tissues such as the placenta.
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loblastomas upon drug treatment (43).
Wnt Pathway Modulators. Like the Hh pathway, Wnt
signaling regulates stem cell self-renewal and differen-
tiation in diverse physiological contexts, including pro-
genitor cell maintenance within the intestinal crypt (44),
hematopoiesis in the bone marrow (45), and the differ-
entiation of melanocytes from neural crest precursors
(46). Aberrant Wnt pathway activation is also associated
with tumorigenesis, such as the onset and mainte-
nance of colorectal cancers (47–49), hepatocellular car-
cinomas (50), and melanomas (51). The Hh and Wnt
TABLE 1. Selected small-molecule modulators of cell fate, continued.
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ing architecture (3). For example, the secretion of active
Wnt protein similarly requires two transmembrane pro-
teins, in this case the acyltransferase Porcupine (Porc),
which modiﬁes the ligand with palmitoleic acid, and the
seven-pass transmembrane protein Wntless (Wls). Wnt
ligands are also palmitoylated, the Frizzled (Fzd) family
of Wnt receptors are the closest known homologues of
Smo, and Wnt target gene expression is regulated by a
phosphorylation- and proteolysis-dependent balance of
transcriptional activators and repressors (Figure 2,
panel b).
In addition to 19 Wnt and 10 Fzd family members, ca-
nonical Wnt signaling in mammals involves low-density-
lipoprotein receptor-related proteins LRP5 and LRP6,
the multifunctional protein adenomatosis polyposis coli
(APC), the scaffolding proteins Axin1 and Dishevelled
(Dvl1, Dvl2, and Dvl3), the T-cell factor/lymphoid
enhancer-binding factor family of transcription factors
(TCF1, TCF3, TCF4, and LEF1), and the transcriptional co-
activator -catenin (Ctnnb1) (3). TCF/LEF family mem-
bers generally repress Wnt target gene expression, but
they are converted into transcriptional activators when
bound to -catenin. Wnt signaling therefore controls
pathway activity by modulating -catenin levels, and in
the absence of Wnt ligands, a cytosolic complex com-
posed of Axin1, APC, CK1, and GSK3 sequentially phos-
phorylates -catenin, thereby promoting its ubiquitina-
tion and proteosomal degradation. The binding of Wnts
to Fzd and LRP5/6 leads to the recruitment of Dvl pro-
teins, LRP5/6 phosphorylation, and consequently Axin1
binding. Since localization of Axin1 to the cell surface
disrupts the cytosolic -catenin degradation complex,
-catenin accumulates in the nuclei of Wnt-stimulated
cells and associates with TCF/LEF proteins to activate
Wnt target gene expression. Wnt-inducible genes in-
clude Axin2, which is functionally equivalent to Axin1
and establishes a negative feedback loop. Loss-of-
functionmutationsinanyofthesegenescancauseava-
riety of developmental abnormalities. For example, inac-
tivating lesions in LRP5 and FZD4 are linked to familial
exudative vitreoretinopathy (52, 53), and loss of WNT7A
function produces limb malformations and joint dyspla-
sia (54). In addition, Wnt pathway-dependent tumors
frequently harbor mutations that cause a loss of APC,
AXIN1, or AXIN2 function or render CTNNB1 insensitive
to ubiquitin-mediated destruction (47–50).
Given the parallels between Hh and Wnt signaling,
one might expect that chemical modulators would
readily target Fzd function. Yet this has not been ob-
Figure 3. TGF superfamily and FGF signaling pathways. Signaling proteins associated with TGF (a) and FGF (b) pathway
regulation are shown. Components or processes that currently can be targeted by small molecules to achieve selective
pathway control are labeled with green (agonist) and red (antagonist) hexagons. Direct small molecule–protein interac-
tions are depicted when known.
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Fzd homologues and their combinatorial expression in
various cell types. Molecules that target other aspects of
Wnt signal transduction, however, have been discov-
ered through cell-based assays and whole-organism
screens, enabling the pharmacological control of both
Wnt signal production and its reception. By screening a
chemical library against murine ﬁbroblasts that overex-
press Wnt3a and harbor a TCF/LEF-responsive reporter,
a family of benzothiazole derivatives called IWPs (inhibi-
tors of Wnt production) were identiﬁed as Porc antago-
nists (55). The same study led to the discovery of two
structural families of IWRs (inhibitors of Wnt response)
that stabilize Axin proteins, leading to their cytosolic ac-
cumulation and increased -catenin degradation. Sub-
sequent investigations have shown that one IWR ligand,
IWR-1, and a structurally unrelated Wnt pathway antago-
nist, XAV939, can inhibit poly-ADP-ribosylating en-
zymes tankyrase 1 and 2, which PARsylate Axin pro-
teins and promote their degradation (56). These
observations indicate that the IWRs and XAV939 inhibit
Wnt pathway activation at least in part by blocking cellu-
lar factors that induce Axin proteolysis.
Conversely, -catenin destruction can be blocked by
small molecules in order to activate the Wnt pathway.
The kinases that prime -catenin for degradation are
possible targets for this purpose, and several selective
inhibitors of GSK3 have been reported to increase Wnt
target gene expression in vitro and in vivo (57, 58).
-Catenin is also stabilized by prostaglandin PGE2,
which apparently acts through cAMP/PKA signaling
(59). Finally, small molecules that prevent the forma-
tion of -catenin-TCF/LEF complexes represent an alter-
native means of controlling Wnt pathway activity. One
advantage of this strategy is that such compounds
would be functionally epistatic to essentially all onco-
genic mutations that abrogate -catenin degradation,
including those in CTNNB1 itself. Toward this goal, sev-
eral thousand natural products were screened for their
ability to disrupt -catenin-TCF4 binding in vitro, result-
ing in the identiﬁcation of PKF115-584 and other
perylene diones as Wnt signaling antagonists that are
effective in both cultured cells and embryos (60).
As expected from the roles of Wnt signaling in stem
cell self-renewal, differentiation, and oncogenesis, Wnt
pathway-modulating compounds are potent regulators
of cell fate. GSK3 inhibitors such as 6-bromoindirubin-
3=-oxime (BIO) and 603281-31-8 have been used to in-
duce both the self-renewal of ESCs and their differentia-
tion to osteoblasts and dopaminergic neurons (58, 61,
62), divergent outcomes that perhaps reﬂect the partici-
pation of GSK3 in pathways other than Wnt signaling
and differences between the ground states of various
ESC lines. PGE2-induced Wnt target gene expression
regulates the self-renewal of hematopoietic stem cells,
and PGE2 and Wnt act synergistically to promote liver re-
generation (63). Pharmacological blockade of Wnt tar-
get gene expression can also perturb stem cell-
dependent processes, as illustrated by the inhibitory ef-
fects of IWR-1 on gastrointestinal tract renewal and cau-
dal ﬁn regeneration in zebraﬁsh (55). Similarly, PKF115-
584 and XAV939 have been shown to block the
proliferation of multiple myeloma cells with constitu-
tively active -catenin and APC-deﬁcient colorectal can-
cer cells, respectively (56, 64).
TGF Superfamily Pathway Modulators. The TGF
superfamily of secreted polypeptides represents an
even larger collection of extracellular factors that regu-
late embryonic patterning and tissue homeostasis.
There are more than 30 TGF family members in mam-
mals, which can be classiﬁed further into the TGF,
bone morphogenetic protein (BMP), Activin/Nodal,
and growth differentiation factor (GDF) subgroups (4).
These intercellular signaling molecules play diverse
roles in cell fate choice, exempliﬁed by the Nodal-
dependent induction of mesoderm and endoderm dur-
ing early embryogenesis and the osteogenic proper-
ties of BMP proteins (65, 66). The relationship
between cancer and TGF superfamily members is
similarly complex. Members of the TGF superfamily
appear to primarily promote cellular senescence, dif-
ferentiation, and apoptosis, and accordingly, TGFand
BMP signaling can actually suppress tumorigenesis.
Inactivating mutations in these pathways have been
found in colorectal tumors (67–69), pancreatic carci-
nomas (70), and head and neck cancers (69). How-
ever, TGF signaling also regulates immune responses
and cell migration, and in certain contexts TGF path-
way activation can protect tumors from the immune
system and promote their metastasis.
All members of the TGF superfamily are secreted as
proteolytically processed homodimers and signal
through a heterotetrameric receptor complex com-
posed of two types of serine/threonine kinases
(Figure 3, panel a) (4). In mammals there are seven
type I receptors (ALKs 1–7) and ﬁve type II receptors
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different receptor combinations are used to recognize
speciﬁc ligands and achieve diverse signaling outputs.
Ligand binding promotes phosphorylation of the type I
receptors by their constitutively active type II counter-
parts, leading to the recruitment and phosphorylation
of intracellular signaling proteins called Smads. These
receptor-regulated Smads (also known as R-Smads 1, 2,
3, 5, and 8) form homo- and heteromeric complexes
with the cofactor Smad4 and then accumulate in the
nucleus to modulate target gene transcription. Speciﬁc
TGF superfamily ligands, receptors, and Smads fre-
quently function with preferred signaling partners,
grossly partitioning into a group composed of BMP/
GDF factors, ALKs 2, 3, and 6, and R-Smads 1, 5, and 8
and another group composed of TGF/Activin/Nodal li-
gands,ALKs4,5,and7,andR-Smads2and3.However,
exceptions to these general trends exist. R-Smad func-
tion is also modulated by inhibitory Smad factors
(Smads 6 and 7), providing yet another layer of path-
way regulation.
Consistent with this large ensemble of TGF super-
family signaling proteins, nearly every organ system re-
quires one or more of these genes for proper patterning
and function, and their genetic disruption has been
linked to several human disorders. For example, loss-of-
function GDF5 mutations can cause limb shortening
and digit loss (71), and inactivating lesions in ALK1 and
BMPR2 are associated with vascular diseases such as
hereditary hemorrhagic telangiectasia and pulmonary
arterial hypertension, respectively (72, 73). Excessive
TGF signaling can be physiologically detrimental as
well, and persistent activation of this pathway often
leads to ﬁbrosis of the kidney, liver, heart, lungs, and
other organs (73). The diversiﬁcation of TGF receptor
signaling outputs through various Smad complexes also
provides a mechanistic basis for the opposing roles of
TGF pathway activation in oncogenesis. Loss-of-
function mutations in the receptors ALK3, ALK5,o rTGF-
BR2 or the cytosolic factor SMAD4 are frequently ob-
served in tumors, and the complete loss of pathway ac-
tivation resulting from these mutations appears to
facilitate the progression of premalignant lesions (67–
70).Certaincancerssuchasbreastcarcinomasandglio-
mas, however, exhibit increased TGF pathway activity
(74, 75). In these cases, the tumor suppressor arm of
TGF signaling may be selectively inhibited, allowing
other TGF pathway-dependent outputs to enhance tu-
mor growth and invasiveness.
To ameliorate these conditions, several screens to
identify small molecules that target TGF superfamily
pathways have been conducted. All known inhibitors of
these signaling mechanisms target type I receptor ki-
nases, and their receptor speciﬁcities generally segre-
gate according to the two subgroups described above.
For example, cell-free kinase inhibitor screens have
identiﬁed a number of compounds that selectively inac-
tivate receptors in the TGF/Activin/Nodal ligand sub-
group (ALKs 4, 5 and 7), such as SB-431542 and SD-
208 (76, 77). In contrast, a zebraﬁsh screen for small
molecules that perturb dorsoventral axis formation led
to the discovery of dorsomorphin, which preferentially
targets type I receptors activated by BMP/GDF ligands
(ALKs 2, 3, and 6) (78). These TGF superfamily antago-
nists can both modulate cell fate decisions and sup-
press tumor progression. The BMP signaling antagonist
dorsomorphin induces cardiomyocyte differentiation in
mouse ESCs (79), and the TGF pathway blocker SD-
208 promotes hematopoiesis and alleviates anemia in
a mouse model of myelodysplastic syndrome, a disease
caused by the constitutive activation of ALK5 in bone
marrow precursors (80). SD-208 also inhibits the growth
and metastasis of gliomas transplanted intercranially
into mice, in part by enhancing the immunogenicity of
these cancers (77). Other type I receptor antagonists
have been used successfully to suppress ﬁbriotic re-
sponses to tissue injury in animal models (81).
FGFPathwayModulators.AswiththeTGFsuperfam-
ily, FGF signaling involves a diverse range of extracellu-
lar ligand and signaling outputs. There are at least 22
members of the FGF ligand superfamily, 18 of which in-
teract with FGF receptors (FGFRs 14 and their splice
variants) (5). Moreover, FGF signaling activates several
downstream signaling modules, including the phospho-
lipase C- (PLC), phosphatidylinositol-3-kinase (PI3K),
and mitogen-activated protein kinase (MAPK) pathways.
This molecular complexity is mirrored by the manifold
roles of FGF signaling in vertebrate physiology, ranging
from mesoderm induction during gastrulation to control
of hair follicle growth in postnatal life (82, 83). Dysregu-
lation of FGF pathway state can lead to skeletal disor-
ders (84, 85), hypogonadism (86), as well as the onset
or progression of multiple myeloma, cervical carcino-
mas, and other human cancers (87, 88).
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dependenthomodimerizationofFGFRs,leadingtotrans-
autophosphorylation by their intracellular tyrosine ki-
nasedomains(Figure3,panelb).Thisprocessincreases
FGFR kinase activity and creates docking sites for down-
stream effectors that contain Src Homology 2 (SH2) or
phosphotyrosine-binding (PTB) domains, enabling the
activated FGFRs to trigger several intracellular signaling
pathways. In the case of MAPK signaling, FGFR substrate
2 (FRS2) is sequestered by the activated FGFR homo-
dimer and phosphorylated, enabling it to recruit the
growth factor receptor-bound 2 (Grb2) adaptor protein
and guanine nucleotide exchange factor Son of seven-
less (Sos) to the plasma membrane. Membrane-
localized Sos then promotes Ras-dependent activation
of Raf kinase, triggering the MEK/ERK kinase cascade
and culminating in the actuation of MAPK-responsive
transcription factors. MAPK pathway target genes in-
clude promoters of G1-phase cell cycle entry and pro-
gression,suchascyclinD1,andprolongedMAPKsignal-
ing is a potent inducer of cell differentiation. In addition
to these signaling mechanisms, FGF-dependent MAPK
pathway activation is negatively regulated by cytoplas-
mic factors, such as the Sprouty (Spry) family of inhibi-
tors that target both Grb2 and Raf and dual-speciﬁcity
phosphatases that inactivate ERK proteins (Dusp6,
Dusp7, and Dusp9). Activated FGFRs can similarly
modulate PLC and PI3K signaling by recruiting and
phosphorylating other effector molecules in FGF-
responsive cells.
Due to the many prominent roles of FGF signaling in
tissue patterning and homeostasis, it is not surprising
that genetic lesions affecting this pathway have been
associated with a large number of human disorders. FGF
ligands are primarily susceptible to loss-of-function mu-
tations. For example, inactivating mutations in FGF3
can cause congenital deafness and structural abnor-
malities of the outer ear and teeth (89), while loss of
FGF8 signaling is associated with salivary and tear gland
defects(90).Incontrast,FGFRscanberenderedinopera-
tive or constitutively active depending on the structural
modiﬁcation. Loss-of-function mutations in FGFR1 have
been linked to Kallmann syndrome, which is character-
ized by hypogonadism, defective olfaction, and in some
cases cleft lip or palate (86). Germline mutations in
FGFR1, FGFR2 and FGFR3 can also lead to their ligand-
independent homodimerization and activation, causing
a broad spectrum of skeletal abnormalities such acro-
cephaly, polysyndactyly, craniosynostosis and dwarﬁsm
(84, 85, 91). Analogous somatic lesions have been
found to promote multiple myeloma, endometrial carci-
noma, and bladder cancer, providing yet another ex-
ample of the molecular kinship between ontogeny and
oncogenesis (87, 88, 92).
Since FGF signaling can lead to the activation of mul-
tiple downstream effectors, each of which can partici-
pate in other signaling pathways, efforts to speciﬁcally
controltheFGFpathwayhavenecessarilyfocusedonthe
most upstream components. FGFR tyrosine kinase activ-
ity is the most obvious pharmacological target, and rela-
tively speciﬁc FGFR inhibitors such as SU5402 and
PD173074 have been developed (93, 94). These an-
tagonists can counteract dysregulated FGF signaling in
cultured cells and animal models, demonstrating pre-
clinical success in models of multiple myeloma, small-
cell lung cancer, and endometrial carcinoma (92, 95,
96). Alternatively, small molecules can be used to selec-
tively target the MAPK, PLC, or PI3K arms of FGF signal-
ing, such as the Raf inhibitor BAY-43-9006 and MEK
antagonistPD0325901(97,98).TheDusp6inhibitor(E)-
2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-
inden-1-one (BCI) has also been used to enhance FGF
Figure 4. Notch signaling pathway. Signaling proteins as-
sociated with Notch signaling are shown. Components that
currently can be inhibited by synthetic molecules to
achieve selective pathway control are labeled with red
hexagons.
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eages in zebraﬁsh embryos (99).
Notch Pathway Modulators. While many aspects of
tissue patterning can be achieved through distinct cellu-
lar responses to secreted factors, certain cellular archi-
tecturesrelyuponsignalingprocessesthatarelimitedto
immediately adjacent cells. The Notch pathway is one
mechanism by which neighboring cells interact (6), and
it is used to promote the self-renewal of hematopoietic
and neuronal progenitor cells in speciﬁc niches (100,
101). Notch signaling is also frequently associated with
lateral inhibition, in which Notch pathway activation in
one cell population suppresses pathway activity in adja-
cent cells. This process can generate structurally com-
plex tissues by simultanously limiting the number of
progenitor cells that adopt a particular cell fate and en-
suring that their neighboring cells are functionally dis-
tinct.Forexample,Notchsignalingisusedtoproducear-
rays of sensory hair cells and supporting cells in the
inner ear (102), to establish segmentation boundaries
during somitogenesis (103), and to determine arterial
versus venous cell fates within the cardiovascular sys-
tem (104).
Activation of the mammalian Notch pathway is initi-
ated by the direct binding of two families of type I trans-
membrane proteins: Notch receptors (Notch 1–4) that
are expressed in one cell population and members of
the Delta-like (Dll1, Dll3, and Dll4) and Jagged (Jag1 and
Jag2) families that are displayed on adjacent cells
(Figure 4) (6). Notch receptors are heterodimeric
proteins, resulting from the furin-mediated cleavage of
a single polypeptide precursor, and their ligand speciﬁc-
ity is regulated in part through glycosylation. Notch
proteins undergo a conformational change upon bind-
ing to Delta-like/Jagged family members, and this struc-
tural shift exposes an extracellular region in Notch proxi-
mal to the transmembrane domain, promoting its
proteolysis by tumor necrosis factor--converting en-
zyme (TACE). The remaining membrane-bound Notch
fragment is then endocytosed and cleaved within its
transmembrane domain by the multiprotein complex
-secretase. This third and ﬁnal proteolytic event re-
leases the Notch intercellular domain (NICD) from the
plasma membrane, allowing it to enter the nucleus and
bind the transcription factor CSL (CBF1/Suppressor of
Hairless/Lag1). CSL normally inhibits Notch target gene
expression by recruiting co-repressors and histone
deacetylases (HDACs) to speciﬁc promoter elements,
and displacement of these proteins by NICD promotes
the association of CSL with transcriptional coactivators
such as the Mastermind-like gene family (MAML1,
MAML2, and MAML3). Notch target genes include mem-
bers of the Hes/Hey family of basic helix–loop–helix
transcriptional repressors, which play critical roles in
stem cell biology.
Perturbations of these Notch pathway components
can lead to aberrant cell fates associated with human
disorders and diseases. For example, inactivation of
NOTCH2 and JAG1 can give rise to Alagille syndrome
(105–107), which is characterized by mispatterning of
the liver, heart, eye, and skeleton, and NOTCH3 muta-
tions have been linked to CADASIL (cerebral autosomal
dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy) (108), a vascular disorder that pri-
marily affects cerebral arteries and causes cognitive and
mood dysfunction. Deformities associated with loss of
Delta-like ligand function have been observed as well, il-
lustrated by the vertebrae segmentation defects associ-
ated with DLL3 mutant alleles (109). In analogy to the
Hh, Wnt, and FGF pathways, Notch signaling can also be
co-opted postnatally to promote the self-renewal in dis-
ease states. Co-expression of JAG1 and NOTCH1 at high
levels correlates with poor clinical outcomes for breast
cancer (110), and the majority of T cell acute lympho-
blastic leukemia/lymphoma (T-ALL) cases are caused by
gain-of-function mutations in NOTCH1 (111).
Small molecules that modulate Notch pathway state
could therefore have signiﬁcant therapeutic value. How-
ever, identifying such compounds has been a chal-
lenge. While Notch pathway activation requires mul-
tiple cellular processes such as receptor proteolysis,
endocytosis, and nuclear transport, these pharmaco-
logically targetable signaling mechanisms are not nec-
essarily unique to the Notch pathway. Furthermore,
Notch receptor/ligand and NICD/CSL complexes may
be difﬁcult to target with small molecules. With one ex-
ception, all synthetic Notch pathway modulators known
todateinhibit-secretase,whichisperhapsbestknown
for its cleavage of amyloid precursor protein (APP). One
of these -secretase antagonists, N-[N-(3,5-
diﬂuorophenacetyl-L-alanyl)]-S-phenylglycine tert-butyl
ester (DAPT) (112), has been used to promote neuronal
regeneration in an animal model of retinal injury (113),
and another, MDL-28170, can induce hair cell formation
in the cochleas of neonate mice (114). Small-molecule
inhibitors of -secretase can also inhibit the progression
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proliferation of their progenitor cells. For example, the
compound MRK-003 decreases Notch target gene ex-
pression in T-ALL cells, leading to their exit from the cell
cycle and programmed cell death (115). Whether the ef-
fects of these compounds on other -secretase sub-
strates will be clinically deleterious remains to be deter-
mined, but the development of small molecules that
selectively block NICD production may be possible since
Notch and APP are processed in distinct cellular com-
partments (116).
The only mechanistically distinct Notch pathway in-
hibitor known to date is not a small molecule but rather
a “stapled” -helical MAML1-derived peptide (SAHM1)
(117). This synthetic, cell-permeable peptide contains
twonon-naturalalkenylaminoacidsthatareconjugated
by ruthenium-catalyzed oleﬁn metathesis, and it can
bind to the NICD/CSL heterodimer and prevent its asso-
ciation with MAML1 to form a transcriptionally active
complex. Consistent with this mode of action, NOTCH1-
dependent T-ALL cells treated with SAHM1 exhibit a set
of downregulated transcripts that is enriched for
-secretase inhibitor-sensitive genes. SAHM1 can also
inhibit T-ALL cell proliferation in vitro and block the pro-
gression of T-ALL cell-dependent leukemia in mouse
models.
Small-Molecule Modulators of Stem Cell
Self-Renewal. The Hh, Wnt, TGF, FGF, and Notch path-
ways therefore constitute a core set of cell fate regula-
tors, and small molecules that selectively modulate
these signaling processes are valuable research and
clinicaltools.However,thesepathwaysalonecannotac-
count for the cellular diversity that is observed in meta-
zoans. Cell fate choice is regulated by a complex net-
work of genetic and epigenetic mechanisms, many of
which have not yet been identiﬁed, and our understand-
ing of how developmental pathways interact with these
pluripotency and differentiation factors is still incom-
plete. To uncover and exploit these regulatory events,
several laboratories have used phenotypic assays to
identify chemical modulators of these cellular pro-
cesses, including known bioactive reagents and syn-
thetic compounds selected for their structural diversity.
Since one challenge in stem cell biology has been
the long-term culture of pluripotent cell lines, technolo-
gies that promote stem cell self-renewal have been of
particular interest. Conventional protocols utilize protein
factors that promote rapid G1-phase transit during cell-
cycle progression and inhibit differentiation, as it is gen-
erally believed that cells are most sensitive to
differentiation-inducing stimuli during early G1 phase.
For instance, mouse ESCs can be maintained in a pluri-
potent state by culturing them in the presence of two ex-
trinsic factors: LIF (leukemia inhibitory factor), a cyto-
kine that binds to the gp130 receptor and activates the
pro-self-renewal STAT3 (signal transducers and activa-
tors of transcription) pathway and the pro-differentiation
MAPK pathway, and BMP4 protein, which induces the
expression of Id (inhibitor of differentiation) proteins
and attenuates the activity of MAPK-responsive tran-
scription factors (118). Thus, the combined actions of
LIF and BMP4 selectively promote mouse ESC self-
renewal. Human ESCs, however, are unresponsive to
LIF and are generally cultured in the presence of either
mouse embryonic ﬁbroblast (MEF) feeder cells, MEF-
conditioned medium, or more recently in deﬁned me-
dium containing recombinant TGF and FGF growth fac-
tors (119). While these mouse and human ESC culture
conditions are generally effective for research applica-
tions, the use of exogenous biological factors restricts
the practical scale at which these cells can be cultured
and introduces batch-dependent differences resulting
from inconsistent growth factor production.
Small molecules that permit the propagation of ESCs
intheabsenceoffeedercells,serum,orextrinsicprotein
factorscouldprovideasolutiontothisproblem,facilitat-
ing the use of pluripotent cells for medical applica-
tions. One approach has been to recapitulate the anti-
MAPK pathway activity of BMP4 with the MEK blocker
PD0325901, while using the GSK3 inhibitor CHIR99021
to release cyclins and other proliferative factors from
GSK3-mediated suppression (120). Using this cocktail
of chemical antagonists, mouse ESCs can be sustained
withoutexogenousgrowthfactorsorcytokines.Otherre-
search groups have conducted chemical screens to
identify new compounds that promote ESC self-renewal,
assessing pluripotency by the expression of alkaline
phosphatase,Nanog,Oct4,Sox2,andothergenesasso-
ciated with the undifferentiated state. One such com-
pound is the dihydropyrimidine pluripotin, and mouse
ESCs cultured in the presence of pluripotin rather than
protein factors can be used to generate derivatives of
the three primary germ layers in chimeric mice, as well
as germline tissues (121). Afﬁnity chromatography stud-
ies revealed that pluripotin binds directly to Ras GTPase-
activating protein and ERK1, and it has been proposed
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inositol-3-kinase (PI3K) arm of Ras signaling to pro-
mote mouse ESC cell cycle progression while inhibit-
ing ESC differentiation induced by Ras-dependent
MAPK pathway activation. It has also been reported
that mouse ESCs cultured in serum-free medium
supplemented with an indole derivative called ID-8
maintain their pluripotency, albeit through an un-
known mechanism of action (122). Whether these
chemical regimens are equally effective at maintain-
ing human ESC pluripotency has not yet been estab-
lished, and it is possible that their cellular targets are
not functionally conserved across species. However,
the ability of TGF and FGF proteins to sustain human
ESCs in deﬁned medium (119) provides at least a
starting point from which small-molecule inducers of
human ESC self-renewal could be developed.
Small-Molecule Modulators of Cell Differentiation.
Just as small molecules can direct ESC regulatory
mechanisms to sustain pluripotency, certain chemicals
have been found to promote the conversion of stem
cells into specialized derivatives. For example, mouse
and human ESCs have been chemically differentiated
into pancreatic progenitor cells through a two-step pro-
cedure (123). First, a screen for small molecules that
promote ESC differentiation into deﬁnitive endoderm re-
vealed two alkyl hydrazone derivatives, IDE1 and IDE2
(123). Cells treated with these synthetic compounds ex-
press a variety of endodermal markers and populate
the developing gut tube when injected into mouse em-
bryos. In fact, the IDE compounds are more effective
endoderm-inducing agents than commonly used pro-
tein factors such as Activin A or Nodal. The precise
mechanism of these small molecules remains unclear,
buttheybothinduceSmad2phosphorylationandNodal
transcription. IDE1 and IDE2 therefore appear to phar-
macologically recapitulate signaling mechanisms nor-
mally initiated by members of the TGF ligand
superfamily.
A second screen for small molecules that promote
the conversion of deﬁnitive endoderm into pancreatic
progenitors was concurrently undertaken, using expres-
sion of the pancreatic marker Pdx1 as an indicator of dif-
ferentiation efﬁciency (124). This study focused on com-
pounds with known cellular targets, and the protein
kinase C activator indolactam V was found to increase
the fraction of Pdx1-expressing cells by over 100-fold
compared to deﬁnitive endoderm treated with a vehicle
control. The indolactam V-induced pancreatic progeni-
tor cells are functionally indistinguishable from those
obtainedthroughgrowthfactortreatments;theyexpress
several pancreatic lineage markers and give rise to
insulin-producing endocrine cells when transplanted
into mice. Sequential treatment of ESCs by IDE1/IDE2
andindolactamVcanthereforeyieldpancreaticprogeni-
tors without a need for exogenous growth factors (123),
achieving an overall conversion efﬁciency greater than
that currently achieved with protein factor-based
protocols.
Chemical library screens have revealed compounds
that facilitate the differentiation of ectodermal and me-
sodermal cell types as well. The aminothiazole deriva-
tive neuropathiazol has been reported to induce the
neuronal differentiation of hippocampal progenitor cells
(125), while sulfonylhydrazones can convert cultured
mouse embryonic carcinomas into cardiovascular pro-
genitor cells (126). The mechanisms by which these
compounds promote lineage-restricted populations
have not been determined, and the functional compe-
tence of these differentiated cells awaits further study.
Preliminary studies of sulfonylhydrazone-induced pro-
genitor cells are promising, however, as they can gener-
ate spontaneously beating cardiomyocytes in cell cul-
ture and contribute to the repair of cryoinjured hearts in
rat models (126).
Small-Molecule Modulators of Cell Reprogramming.
One of the most transformative scientiﬁc breakthroughs
in this decade has been the discovery that transient
overexpression of a few transcription factors can repro-
gram differentiated cells into pluripotent populations,
commonly referred to as induced pluripotent stem (iPS)
cells.Thiswasﬁrstachievedbyexpressingthetranscrip-
tion factors Oct4, Sox2, Klf4, and c-Myc in MEFs using
retroviruses, and the resulting iPS cells are functionally
identical to mouse ESCs (127). The technology has sub-
sequently been applied to human cells (128), and iPS
cells could signiﬁcantly advance the development of
cell-based therapies for human disorders and diseases.
Fully realizing the biomedical potential of iPS cells,
however, will require addressing certain challenges.
First, somatic cell reprogramming is very inefﬁcient and
slow, with typically 0.01% of virally infected ﬁbroblasts
giving rise to ESC-like colonies after two to three weeks.
Second,theintegrationofthesevectorsintothehostge-
nome can have deleterious effects. Third, although ex-
pression of the exogenous reprogramming factors is
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a signiﬁcant risk of tumorigenesis if these exogenous
genes are inadvertently reactivated. In particular, c-Myc
and Klf4 are known oncogenes, and a high incidence of
cancer has been observed in chimeric mice derived
from germline-competent iPS cells (129).
While several genetic methods have been employed
to bypass these issues (130−132), the possibility of us-
ing small molecules to increase the efﬁciency of iPS
cell generation or to functionally replace one or more re-
programming factors has been explored by a number
of laboratories. Compounds that promote chromatin re-
modelinghavebeenofparticularinterestbecauseofthe
critical roles of DNA and histone modiﬁcations in estab-
lishing and maintaining differentiated cell fates. For ex-
ample, the HDAC inhibitor valproic acid has been re-
ported to increase four-factor reprogramming efﬁciency
by nearly 400-fold and iPS cell clones can even be ob-
tained from valproic acid-treated human ﬁbroblasts
transduced with only Oct4 and Sox2 (133). Recent stud-
ies further suggest that blocking the methylation of
DNA or histones can similarly facilitate cell dedifferentia-
tion. When applied at the appropriate time during so-
matic cell reprogramming, the DNA methyltransferase
inhibitor 5-azacytidine can improve the efﬁciency of iPS
cell generation by approximately 100-fold (134). Simi-
larly, using the G9a histone methyltransferase inhibitor
BIX-01294 and the DNA methyltransferase inhibitor
N-phthalyl-tryptophan (also known as RG108) in combi-
nation has been reported to promote the dedifferentia-
tion of mouse embryonic ﬁbroblasts transduced with
only Oct4 and Klf4 (135).
More recently, compounds that target upstream sig-
naling pathways have been pursued as an alternative
strategy for optimizing iPS cell induction. In a large-
scale, high-throughput screen for small molecules that
can functionally replace Klf4, it was determined that the
benzazepinone kenpaullone can work with Oct4, Sox2,
and c-Myc to convert murine embryonic ﬁbroblasts into
iPS cells, albeit at a lower efﬁciency than that observed
with the complete set of reprogramming factors (136).
The mechanism by which this compound promotes cell
dedifferentiation, however, is unknown and will likely be
difﬁcult to decipher. Kenpaullone can inhibit GSK3 and
several cyclin-dependent kinases, and short-hairpin
RNA-mediated silencing of these kinases, either indi-
viduallyorincombination,doesnotincreasetheexpres-
sion of ESC markers. These observations suggest ken-
paullone may act through a novel and perhaps complex
mechanism.
Approaches that speciﬁcally target developmental
signalingpathwayshavebeensuccessfulaswell.Forex-
ample, TGF pathway antagonists such as SB-431542
can increase the efﬁciency of four-factor reprogramming
of murine ﬁbroblasts by 30-fold and permit their conver-
sion into iPS cells using three-factor protocols that lack
either Sox2 or c-Myc (137). TGFsignaling blockade can
also reduce the time required for efﬁcient cell repro-
gramming from weeks to days. While inhibiting TGF
pathway activation alone does not improve the efﬁ-
ciency of human iPS cell induction (137), it has been re-
ported that using SB-431542 and the MEK inhibitor
PD0325901 in combination can improve the efﬁciency
and rate of this process by 100- and 4-fold, respectively
(138). Presumably these compounds activate prolifera-
tive and/or inhibit pro-differentiation signaling mecha-
nisms, but the precise mechanisms by which they facili-
tate somatic cell reprogramming are unclear. Moreover,
since TGF and FGF signaling has been found to pro-
mote human ESC self-renewal (119), the duration of SB-
431542 and PD0325901 treatment may inﬂuence the
utility of this approach.
Concluding Remarks. The demand for small mol-
ecules that can control cell fate continues to grow. In
part, this need arises from the dynamic and combinato-
rial manner in which signaling pathways control cell plu-
ripotency and differentiation state, mechanisms that
can be difﬁcult to recapitulate with current genetic tech-
nologies but can be approximated through the applica-
tion of one or more chemical reagents at speciﬁc times,
durations, and doses. Chemical modulators of cell fate
similarly offer certain advantages over biologic ap-
proaches for the treatment of human diseases and dis-
orders. Small molecules can readily interact with intra-
cellular signaling molecules that might be inaccessible
to protein-based therapies, and the ability of com-
pounds to simultaneously target homologous proteins
can be beneﬁcial in certain therapeutic contexts. From a
practical point of view, there also are well-established
procedures for producing, testing, and administering
pharmaceutical-grade compounds, while safe practice
guidelines for virus- and cell-based therapies and other
biologic approaches are still under development.
Yet despite this potential, the spectrum of com-
pounds that can be used to study and therapeutically
manipulate cell fate choice is still narrow. For example,
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regulated by an ensemble of signaling proteins, but in
most cases only one or two of these factors have known
small-molecule modulators. Smo is the most common
pharmacological target within the Hh pathway, Wnt
pathway modulators predominantly abrogate tankyrase
and GSK3 activities, all known inhibitors of the TGFsu-
perfamily block type I receptor kinase activity, and all
but one of the reported Notch pathway antagonists tar-
get the -secretase protein complex. This lack of mecha-
nistic breadth limits the range of biological systems
that can be pharmacologically controlled, particularly
with respect to disease states caused by mutations in
speciﬁc developmental pathway components. Moreover,
tankyrase, GSK3, and -secretase functions are not re-
stricted to Wnt or Notch pathway regulation, and inhibi-
tors of these enzymatic activities will likely perturb mul-
tiple signaling processes in vivo. Whether this targeting
bias is primarily due to the inherent small-molecule sen-
sitivity of individual signaling proteins versus the limited
structural diversity of current chemical libraries is not
clear. It is likely, however, that expanding our repertoire
of chemical probes will require both new assays of pro-
tein function and compound collections with greater mo-
lecular complexity. Small molecules that selectively in-
hibit Hh protein biogenesis or Ptch1 activity, regulate Fzd
receptorfunction,activateTGFsignalingpathways,actu-
ate FGFRs, or abrogate NICD/CSL function, to name a few
examples, would be especially desirable.
The development of small molecules that can modu-
late cell self-renewal, differentiation, and reprogram-
ming through other cellular targets is also in a nascent
stage. Although a few of these compounds have known
biological activities, the mechanisms by which they in-
ﬂuence cellular states are not well understood. Indeed,
the ability of these small molecules to perturb multiple
signaling proteins may be an essential aspect of their
cellular phenotypes. Valproic acid, BIX-01294,
5-azacytidine, N-phthalyl-tryptophan, and other chemi-
cal reagents that alter chromatin structure affect the ex-
pressionofhundredsifnotthousandsofgenes,anditis
possible that pluripotin, IDE1/IDE2, indolactam V, and
kenpaullone also act through complex mechanisms.
The wide-ranging effects of these compounds on signal-
ing pathways and gene transcription make it challeng-
ing to decipher how they inﬂuence stem cell biology. It
is also uncertain how broadly these compounds can be
applied to induce or maintain speciﬁc cell fates.
Reliably and efﬁciently controlling cell fate with
chemical reagents will likely require a more deliberate
approach, using compounds that rival endogenous fac-
tors with respect to potency and selectivity. While phe-
notypicscreenswillcontinuetoplayanimportantrolein
these efforts, identifying new compounds that can
modulate cell pluripotency and differentiation in certain
contextsisonlyastartingpoint.Establishingtheirmech-
anisms of action with biochemical and genetic rigor
and thoroughly investigating their applicability to other
biological systems is essential for maximizing the im-
pact of these small molecules at the laboratory bench
and in the clinic. In addition, new strategies for the dis-
covery of cell fate regulators, including more targeted
approaches, will undoubtedly arise as we gain new in-
sights into stem cell biology. For example, future com-
pounds could target cellular mechanisms that link de-
velopmental signaling pathways to pluripotency factor
networks and differentiation programs, regulate cellular
and genomic responsiveness to differentiation-inducing
signals, or alter cell cycle dynamics to favor pluripotent
or committed states. Chemical biologists therefore have
an opportunity to make unique contributions to our un-
derstanding of how pluripotent cells self-renew and dif-
ferentiate, as well as our ability to control these pro-
cesses for therapeutic purposes. Through these efforts,
we may someday have pharmacological agents that
help remediate vision or hearing loss, spinal cord inju-
ries, cardiac ischemic damage, neurodegenerative dis-
eases, and malignant tumors. Realizing these possibili-
ties is an exciting prospect, a fate that the chemistry
community should not leave entirely to chance.
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